Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
- Primary completion Nov 19, 2026Sponsor estimatePhase 1NCT07428759Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 YearsGlaxoSmithKline · Pneumonia, BacterialActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT02704858Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaNeonc Technologies, Inc. · Glioblastoma MultiformeActive, not recruitingNTHILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple MyelomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT04735978Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursReplimune, Inc. · Advanced Solid TumorActive, not recruitingREPLLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT05094336A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Amgen · Advanced MTAP-null Solid TumorsActive, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT05095727A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)ModernaTX, Inc. · Glycogen Storage DiseaseActive, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT05688475A Rollover Study of CC-122Bristol-Myers Squibb · Non-Hodgkin LymphomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT07377539A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy ParticipantsJazz Pharmaceuticals · Healthy ParticipantsActive, not recruitingJAZZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 1NCT00819546RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSRichard Stone, MD · Acute Myeloid LeukemiaActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT02573896Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsNew Approaches to Neuroblastoma Therapy Consortium · NeuroblastomaActive, not recruitingUTHRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT02826434Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerMassachusetts General Hospital · Breast CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT03610711REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other...Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Gastroesophageal CancerActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT04192981GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal MetastasesMemorial Sloan Kettering Cancer Center · Brain MetastasesActive, not recruitingKZIACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT04367675INO 5401 Vaccination in BRCA1/2 Mutation CarriersUniversity of Pennsylvania · BRCA1/2 MutationActive, not recruitingINOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT04989946Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed...University of Wisconsin, Madison · Prostate CancerActive, not recruitingREGNCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT05082259ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabInstitute of Cancer Research, United Kingdom · Advanced CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05099666Lurbinectedin + Doxorubicin In LeiomyosarcomaMassachusetts General Hospital · Advanced Soft-tissue SarcomaActive, not recruitingJAZZCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05205330Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersRottapharm Biotech · Refractory Metastatic Colorectal CancerActive, not recruitingAGENCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05262023A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants...Denali Therapeutics Inc. · Frontotemporal DementiaActive, not recruitingDNLILeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT05378425A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With PembrolizumabNectin Therapeutics Ltd · CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05546268Study of Oral MRT-2359 in Selected Cancer PatientsMonte Rosa Therapeutics, Inc · NSCLCActive, not recruitingGLUELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT05653752A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast CancerMediLink Therapeutics (Suzhou) Co., Ltd. · Non Small Cell Lung CancerActive, not recruitingBNTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05664243A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination...In8bio Inc. · GlioblastomaActive, not recruitingINABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05885464A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell...Beam Therapeutics Inc. · Lymphoblastic LymphomaActive, not recruitingBEAMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05925608Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem CellsBioCardia, Inc. · Heart Failure, SystolicActive, not recruitingBCDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 83 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.